Trial Profile

Managed Access Program (MAP) Cohort Treatment Plan CLEE011A2408 to Provide Access to Ribociclib (LEE011, Kisqali®), for Locally Advanced or Metastatic Cancer Resistant or Refractory to Available Treatment Options and Candidate for Therapy With a CDK Inhibitor (Including Tumors With D-cyclin-CDK4/6-INK4a-Rb Pathway Abnormalities)

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 12 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Nov 2023 CLEE011A2006M is added for providing expanded access of ribociclib as adjuvant therapy for early-stage HR+HER2 breast cancer.
03 Nov 2023 Status changed from completed to recruiting.
15 Feb 2022 Status changed from recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com